Podcasts about life sciences

On March 20th, 1995, the Tokyo subway system was flooded with sarin nerve gas in a coordinated terrorist attack by the religious cult Aum Shinrikyō. Led by the charismatic new-age guru, Shoko Asahara, the well-funded and technologically ambitious Aum organization manufactured and deployed chemical weapons in an attempt to bring about the end of the world. In the chaos that followed, 13 people were killed, thousands were injured, and the international community shuddered at the possibility of future attacks by fringe political groups.    SOURCES: Amarasingam, A. (2017, April 5). A history of sarin as a weapon. The Atlantic.  Cotton, Simon. “Nerve Agents: What Are They and How Do They Work?” American Scientist, vol. 106, no. 3, 2018, pp. 138–40.  Danzig, Richard; Sageman, Marc; Leighton, Terrance; Hough, Lloyd; Yuki, Hidemi; Kotani, Rui; Hosford, Zachary M.. Aum Shinrikyo: Insights Into How Terrorists Develop Biological and Chemical Weapons . Center for a New American Security. 2011. Gunaratna, Rohan. “Aum Shinrikyo's Rise, Fall and Revival.” Counter Terrorist Trends and Analyses, vol. 10, no. 8, 2018, pp. 1–6.  Harmon, Christopher C. “How Terrorist Groups End: Studies of the Twentieth Century.” Strategic Studies Quarterly, vol. 4, no. 3, 2010, pp. 43–84. JSTOR, http://www.jstor.org/stable/26269787.  “IHT: A Safe and Sure System — Until Now.” The New York Times, 21 Mar. 1995. Jones, Seth G., and Martin C. Libicki. “Policing and Japan's Aum Shinrikyo.” How Terrorist Groups End: Lessons for Countering al Qa'ida, RAND Corporation, 2008, pp. 45–62.  Kaplan, David E. (1996) “Aum's Shoko Asahara and the Cult at the End of the World”. WIRED.  Lifton, Robert Jay. Destroying the World to Save It: Aum Shinrikyo, Apocalyptic Violence, and the New Global Terrorism. 1999. Murakami, Haruki. Underground: The Tokyo Gas Attack and the Japanese Psyche. Translated by Alfred Birnbaum and Philip Gabriel. 2001. Murphy, P. (2014, June 21). Matsumoto: Aum's sarin guinea pig. The Japan Times.  Reader, Ian. Religious Violence in Contemporary Japan: The Case of Aum Shinrikyo.  2000. Tucker, Jonathan B. “Chemical/Biological Terrorism: Coping with a New Threat.” Politics and the Life Sciences, vol. 15, no. 2, 1996, pp. 167–83.  Ushiyama, Rin. “Shock and Anger: Societal Responses to the Tokyo Subway Attack.” Aum Shinrikyō and Religious Terrorism in Japanese Collective Memory., The British Academy, 2023, pp. 52–80.  Learn more about your ad choices. Visit megaphone.fm/adchoices

Episode 5 of Standard Deviation with Oliver Bogler on the Out of Patients podcast feed pulls you straight into the story of Dr Ethan Moitra, a psychologist who fights for LGBTQ mental health while the system throws every obstacle it can find at him.Ethan built a study that tracked how COVID 19 tore through an already vulnerable community. He secured an NIH grant. He built a team. He reached 180 participants. Then he opened an email on a Saturday and learned that Washington had erased his work with one sentence about taxpayer priorities. The funding vanished. The timeline collapsed. His team scattered. Participants who trusted him sat in limbo.A federal court eventually forced the government to reinstate the grant, but the damage stayed baked into the process. Ethan had to push through months of paperwork while his university kept the original deadline as if the shutdown had not happened. The system handed him a win that felt like a warning.I brought Ethan on because his story shows how politics reaches into science and punishes the people who serve communities already carrying too much trauma. His honesty lands hard because he names the fear now spreading across academia and how young scientists question whether they can afford to care about the wrong population.You will hear what this ordeal did to him, what it cost his team, and why he refuses to walk away.RELATED LINKSFaculty PageNIH Grant DetailsScientific PresentationBoston Globe CoverageFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this episode of Tiny Show and Tell Us, we read an email from a listener who, as a kid, shared a fun fact with her classroom: polar bears have black skin. Her teacher not only told her she was wrong but embarrassed her in front of the other students. Well, it's time to set the record straight. Polar bears do, in fact, have black skin and we do, in fact, love a grudge and are so glad to provide vindication. Then we talk about the hidden world of insect vibrational communication.We need your stories — they're what make these bonus episodes possible! Write in to tinymatters@acs.org *or fill out this form* with your favorite science fact or science news story for a chance to be featured.A transcript and references for this episode can be found at acs.org/tinymatters.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Life Science Logistics, LLC v. United States

Chelsea J. Smith walks into a studio and suddenly I feel like a smurf. She's six-foot-three of sharp humor, dancer's poise, and radioactive charm. A working actor and thyroid cancer survivor, Chelsea is the kind of guest who laughs while dropping truth bombs about what it means to be told you're “lucky” to have the “good cancer.” We talk about turning trauma into art, how Shakespeare saved her sanity during the pandemic, and why bartending might be the best acting class money can't buy. She drops the polite bullshit, dismantles survivor guilt with punchline precision, and reminds every listener that grace and rage can live in the same body. If you've ever been told to “walk it off” while your body betrayed you, this one hits close.RELATED LINKS• Chelsea J. Smith Website• Chelsea on Instagram• Chelsea on Backstage• Chelsea on YouTube• Cancer Hope Network• Artichokes and Grace – Book by Chelsea's motherFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Introduction: In this episode, host Sandy Vance sits down with Joerg Schwarz, Senior Director of Industry Strategy & Solutions for Healthcare Interoperability at Infor, and Adam Luff, a healthcare technology executive and VP of Solution Consulting at Infor. Together, they take a fascinating look at the real-world state of healthcare data. Together, they unpack what AI is actually doing for the industry, why pulling meaningful information from existing systems is so challenging, and how proprietary schemas and non-queryable databases keep organizations stuck with costly “zombie systems.” They explore the promise of using AI to finally unlock that trapped data, along with the critical measures needed to ensure accuracy, quality, and transparency as new technologies evolve. Make sure to check out this episode if you've ever wondered what's behind the “black box” of healthcare data.In this episode, they talk about:What AI does for the healthcare industryThe challenges that come with extracting dataWhy the data in current databases isn't searchable and queryableProprietary schemas Unable to pull one data table at a timeUsing AI to extract data from zombie systems The time and money it takes to keep zombie systems aliveMeasures with new tech that need to be taken to ensure accuracy and qualityTransparency and rejecting the “black box” approachA Little About Joerg and Adam:As a trusted and highly skilled Global Business Strategy Executive and seasoned thought leader in the Healthcare IT domain, Joerg keeps an acute focus on the customer while leading teams, building strategic partnerships, and delivering solutions with measurable outcome improvements. His knowledge runs wide and deep with a 360-degree vantage point through the lenses of Technology, Sales, Marketing, and Academia. He combines the realities of leading key stakeholders and teams through innovation with respect to Healthcare IT and Life Sciences throughout his distinguished career. Joerg is highly motivated towards the evolution of connected managed care, population health, and clinical analytics. Communicating complexity is a signature quality Joerg possesses in service to delivering mutual benefit "win-win-win's" by successfully navigating complex problems, accelerating brand and product growth, and being a key contributor in go-to-market decisions.Adam Luff is a healthcare technology executive and VP of Solution Consulting at Infor. With his 25 years in the Healthcare Technology industry, Adam focuses on operational efficiency that leads to providers getting paid faster and simpler.

Mark Kramer is voorzitter van de Vereniging Innovatieve Geneesmiddelen (VIG).***Volg Leaders in Life Sciences via de website.Volg Leaders in Life Sciences via LinkedIn.Bezoek www.henkjanout.nl voor meer informatie over de host.***Vragen, suggesties of feedback? Graag! Stuur een email naar: henkjan.out@me.com***Vind jij de Leaders in Life Sciences podcast leuk? Dan zouden we het enorm waarderen als je een recensie zou willen achterlaten op Apple Podcasts of een vijf sterren beoordeling zou willen geven op Spotify.Jouw steun betekent veel voor ons, omdat het anderen kan aanmoedigen om de podcast ook te gaan beluisteren. Heel erg bedankt!***Leaders in Life Sciences wordt mede mogelijk gemaakt door Pivot Park, Pedersen & Partners en Johnson & Johnson Innovative Medicine.

This podcast is brought to you by Outcomes Rocket, your exclusive healthcare marketing agency. Learn how to accelerate your growth by going to⁠ outcomesrocket.com Innovation is moving faster than the law, and investors are racing to keep up. In this episode, Brian Bewley, a partner in the Life Sciences and Health Industry group at Reed Smith, discusses how rapid technological advancements are reshaping healthcare and the life sciences faster than current regulations can keep pace. He explains how shifting federal policies, tariff disruptions, and turnover at key agencies, such as the FDA and HHS, have created uncertainty for investors. Brian also discusses how state-level laws are making it harder for private equity to fund healthcare innovation, and why that could slow progress. Still, he sees growing optimism as investors engage policymakers and prepare for a stronger market in 2026. Tune in to learn how legal, regulatory, and investment forces are converging to shape the future of healthcare innovation! Resources Connect with and follow Brian Bewley on LinkedIn, or reach out via email. Follow Reed Smith LLP on LinkedIn and visit their website.

Season 4, Episode 12: Jack Stone and Alex Gornik sit down with Jon Schultz, Co-Founder and Managing Principal of Onyx Equities, one of the Northeast's most active private real estate firms. Schultz—known for turning around complex office, industrial, and retail assets—shares how Onyx repositions properties, adapts across cycles, and captures value in a rapidly evolving market. From life sciences and medical office to AI-driven data centers, he breaks down the trends reshaping the tri-state region, the lessons learned from decades of leadership, and why success now depends on being “customer-obsessed. TOPICS 00:00 – Introduction 02:10 – Early Career and Founding Onyx Equities 06:15 – Navigating Market Cycles and Value Creation 09:30 – Office Market Shifts and Tenant Demand 12:45 – Life Sciences and Medical Office Expansion 17:40 – Inside the Data Center Gold Rush 22:15 – Rates, Debt, and Opportunities Ahead 27:48 – Tri-State vs. Sun Belt Market Dynamics 34:05 – Leadership, Adaptability, and Lessons Learned 42:30 – Building a Brand Tenants Trust Shoutout to our sponsor, Lev. The AI-powered way to get real estate deals financed. For more episodes of No Cap by CRE Daily visit https://www.credaily.com/podcast/ Watch this episode on YouTube: https://www.youtube.com/@NoCapCREDaily About No Cap Podcast Commercial real estate is a $20 trillion industry and a force that shapes America's economic fabric and culture. No Cap by CRE Daily is the commercial real estate podcast that gives you an unfiltered ”No Cap” look into the industry's biggest trends and the money game behind them. Each week co-hosts Jack Stone and Alex Gornik break down the latest headlines with some of the most influential and entertaining figures in commercial real estate. About CRE Daily  CRE Daily is a digital media company covering the business of commercial real estate. Our mission is to empower professionals with the knowledge they need to make smarter decisions and do more business. We do this through our flagship newsletter (CRE Daily) which is read by 65,000+ investors, developers, brokers, and business leaders across the country. Our smart brevity format combined with need-to-know trends has made us one of the fastest growing media brands in commercial real estate.

Daiichi Sankyo has been pioneering ADCs since 2010, with a pipeline targeting over 30 indications and potentially reaching 400,000 patients.In today's episode I'm joined by Dr. Markus Kosch, Head of the EU Oncology Business Division at Daiichi Sankyo. A physician by training with a deep academic background in oncology, Markus has spent over two decades advancing cancer care, from clinical practice to leadership roles shaping strategy across Europe and Canada. Since joining Daiichi Sankyo in 2021, he has been at the forefront of one of the industry's most ambitious ADC pipelines, overseeing more than 60 clinical trials across 24 countries and driving landmark approvals that are redefining treatment in breast, lung, and gastric cancers.This week's episode is brought to you with the support of Kadans. Looking for the perfect space to grow your Life Sciences company? Kadans Science Partner is Europe's leading provider of cutting-edge lab and offices spaces, tailored to your needs. Kadans puts you at the centre of innovation, giving you the chance to connect with top researchers, universities, and investors through its international network. Here, you'll join a vibrant community of innovators driving real change. Are you ready to take your research to the next level? Learn more at kadans.com – where innovation thrives. 01:45.         Meet Markus Kosch03:12.         Clinical background shaping an industry role04:46.         Daiichi Sankyo's 40-year oncology legacy06:19.         European investments and Munich hub10:34.         ADC platform strengths explained14:20.         Key ESMO 2025 trial dataClarification: The reference to ‘TB01' at 16:24 refers to the TROPION-Breast02 clinical trial, not TB01.19:43.         Managing risks and partnerships23:35.         Patient advocacy in trial design33:59.         Future of oncology and ADCsInterested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletterTo dive deeper into the topic: 10 oncology deals in 2025 spotlight where industry leaders are betting bigAstraZeneca and Daiichi Sankyo's Enhertu recommended for approvalTen drugs to watch in 2025: will these therapies become blockbusters?

In today's episode, we chat with author Sam Kean about his new book Dinner with King Tut and learn how researchers and citizen scientists are recreating ancient recipes, tools, and technologies — from wound remedies with pennies to inventive pottery glazed in blood — and how experimental archaeology is changing our understanding of the past. Send us your science facts, news, or other stories for a chance to be featured on an upcoming Tiny Show and Tell Us bonus episode. And, while you're at it, subscribe to our newsletter!All Tiny Matters transcripts and references are available here.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Was bringt eine Life-Science-Strategie für Österreich? Diese Frage stand im Mittelpunkt des Branchentalks der „Presse“ und der Pharmig. Eine Diskussion über die Stärken und Schwächen des Standorts und darüber, wie es um die Wettbewerbsfähigkeit bestellt ist.

Wie bringt man echte Energie ins Lernen – statt langweiligem Multiple Choice? Genau darum geht's in dieser Folge. Jan spricht mit Jürgen Kupper, Gründer von KvizMe, einer Lernplattform, die aus Folien, Webseiten oder Videos automatisch Quizfragen erstellt, die wirklich aufs Verstehen testen. Lernende sprechen ihre Antworten einfach ins Handy und bekommen sofort individuelles Feedback. Gemeinsam diskutieren die beiden, warum das gerade in Bereichen wie Medizintechnik und Pharma so wichtig ist – dort, wo falsches Verstehen echte Konsequenzen haben kann. Außerdem geht's um Vertrieb, den Einstieg in träge Märkte und die Kunst, sich einen ersten „Beach head“ zu erobern. Und: Jürgen zeigt, warum Quizformate ein starkes Mittel gegen den aktuellen SEO-Schmerz sein können, weil sie Nutzerinnen und Nutzer aktiv ins Lernen reinziehen. Eine Folge für alle, die Menschen in Bewegung bringen wollen, ob in Projekten, Teams, Organisationen oder Kundengesprächen. Denn wenn wir verstehen, wie Lernen wirklich Energie erzeugt, wie man komplexe Inhalte spielerisch vermittelt und wie man neue Ideen in trägen Märkten zum Fliegen bringt, dann hilft das nicht nur Lehrenden, sondern allen, die etwas verändern oder voranbringen wollen. Viel Spaß beim Hören! Über die Personen [Gast] Jürgen Kupper verbindet über 15 Jahre internationale Erfahrung im Marketing und Business Management der Life-Science- und Healthcare-Branche mit einer tiefen Leidenschaft für modernes Lernen. Als Professor für Mediendidaktik und E-Learning an der Medical School Hamburg entwickelt er seit Jahren innovative Lehrformate und kennt die Herausforderungen von Wissensvermittlung aus der Praxis wie aus der Forschung. Er ist seit März 2025 CEO von KvizMe und dort für das Produktmanagement und den Vertrieb zuständig. [Gastgeber] Dr. Jan Evers ist erfahrener Gründungsberater und selbst Unternehmer. Jan berät seit fast 20 Jahren Banken und Ministerien sowie wachstumsstarke Gründer*innen und Mittelständler – als Aufsichtsrat, Business Angel und Miteigentümer. Mehr Infos zu Jan: https://everest-x.de/profil/ [Redaktion] Gesa Holz, Sarah Bechtloff [Technische Bearbeitung] Anne de ChénerillesWeitere Themen: LaborX Hamburg⁠⁠ – ⁠⁠Ideencouch #66 Geschäftsmodellarbeit⁠⁠ –⁠⁠Ideencouch #71 Digitale Geschäftsmodelle⁠⁠ -  Ideencouch#33 Vertrieb und Kaltakquise – Ideencouch #74  Online-Marketing - #105  Wie KI die Weiterbildung revolutioniertÜber die Ideencouch: Die Ideencouch ist ein Podcast von EVEREST. Wenn du Gründer*in bist, dich Startups faszinieren oder du als Unternehmer*in an deinem eigenen Unternehmen arbeitest, ist dieser Podcast genau der richtige für dich. Aus den Gesprächen zwischen Jan und seinen Gästen wirst du praktisches Wissen, anwendbare Erkenntnisse und kreative Anregungen für deinen Unternehmer*innen-Alltag mitnehmen. -- Du möchtest uns Feedback geben oder selbst Gast im Podcast sein? Schreib uns eine E-Mail an info@laborx-hamburg.de Wir freuen uns auf deine Nachricht! -- Partner -- LaborX --  Gründerplattform -- Firmenhilfe   --SmartBusinessPlan – Smart Business Control

When Julia Stalder heard the words ductal carcinoma in situ, she was told she had the “best kind of breast cancer.” Which is like saying you got hit by the nicest bus. Julia's a lawyer turned mediator who now runs DCIS Understood, a new nonprofit born out of her own diagnosis. Instead of panicking and letting the system chew her up, she asked questions the industry would rather avoid. Why do women lose breasts for conditions that may never become invasive? Why is prostate cancer allowed patience while breast cancer gets the knife? We talked about doctors' fear of uncertainty, the epidemic of overtreatment, and what happens when you build a movement while still in the waiting room. Funny, fierce, unfiltered—this one sticks.RELATED LINKS• DCIS Understood• Stalder Mediation• Julia's story in CURE Today• PreludeDx DCISionRT feature• Julia on LinkedInFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

過去一年，你有沒有也覺得自己被各種 AI 相關內容鋪天蓋地地轟炸？從遇到疑難雜症請它幫忙搜尋、整理資料、處理公事，到純粹當成娛樂、請它生成各種有趣圖片，AI 的應用就像當年的網路搜尋一樣，幾乎無所不在地滲入我們的生活。 這集的三腳貓實驗室裡，在日常工作與生活中頻繁使用 AI 的「一般用戶」浩文和天豪，以及在生醫產業中運用 AI 參與藥物研究，並時刻關注AI前沿發展進程的「高階玩家」Mike，一起來聊聊現在 AI 在生醫學者日常中的各種使用場景，還有目前在大眾應用層面上的發展與限制。 我們或許已經習慣打開 AI 工具的網頁，在介面裡點選、輸入、獲得服務，就像多年前逐漸習慣使用 Google 一樣。但我們準備好迎接下一個階段了嗎？一個可以自己設計、客製化各種 Agent，自動幫你處理需求的時代？面對功能愈來愈強大的 AI 工具，你是否也開始擔心，身為「人」在科學研究中的角色，會不會很快被取代？歡迎你來聽聽這一集，和我們一起思考、一起面對這個正洶湧而來的新時代。 相關連結 如何使用AI工具提升科學研究生產力: Dr. Candice Chu's talk https://www.youtube.com/watch?v=CTTESpCK4yc https://www.nature.com/articles/d41586-024-03775-7 Chain of thought prompting: https://www.prompthub.us/blog/chain-of-thought-prompting-guide https://research.google/blog/accelerating-scientific-breakthroughs-with-an-ai-co-scientist/ 工作人員 內容製作：MIke、浩文、天豪 後製：天豪 文案：天豪 音樂：雯薇 封面：雯薇 上架：天豪 宣傳：Angel、雯薇 -- Hosting provided by SoundOn

Darum geht es in der dritten Folge der zweiten Staffel Future FINANCE.Lohnt sich ein Jobwechsel jetzt überhaupt? Und wenn ja, welche Skills sollte ich mitbringen, um mich von der Masse abzuheben? In der neuen Folge von Future FINANCE gibt Personalberater Erich Schwinghammer konkrete Einblicke, welche Profile mit Top-Gehältern vergütet werden. Die zentrale Botschaft: Es geht längst nicht mehr nur um Zahlenkompetenz. Gefragt sind Finanzprofis, die strategisch denken, mutig Entscheidungen treffen und Technologie als Karriere-Turbo verstehen. Schwinghammer macht deutlich, dass gerade in herausfordernden Marktphasen die richtigen Weichenstellungen über die Karriere entscheiden.Zu Erich SchwinghammerErich Schwinghammer ist seit rund 20 Jahren als Personalberater im Bereich Finance tätig. Seit 2011 ist er bei der Personalberatung Hays aktiv und agiert seit 2023 als Bereichsleiter Finance und HR.Sie haben noch Fragen an Erich Schwinghammer? Hier können Sie ihn erreichen: Erich Schwinghammer | LinkedInHier können Sie sich anschauen, was unser Kooperationspartner Hays macht: https://www.hays.de/personaldienstleistung/fachgebiete-finance-festanstellung?utm_campaign=finance_…Hays ist einer der weltweit führenden Personaldienstleister für qualifizierte Fach- und Führungskräfte. Dabei bringen die Experten für Rekrutierung Unternehmen mit Spezialistinnen und Spezialisten zusammen und sorgen für das perfekte Matching. Neben Finance vermittelt Hays Expertinnen und Experten u.a. aus den Bereichen Engineering, IT, HR, Life Science und Sales & Marketing.

On this episode Justin records live at HLTH25 in Las Vegas. Stay tuned for the next few weeks to hear all his guests. This week Justin talks to Rasu Shrestha, MD MBA, Chief Innovation and Commercialization Officer, EVP at Advocate Health and Rowland Illing, MD. Global Chief Medical Officer and Director, Healthcare and Life Sciences at Amazon Web Services (AWS). To stream our Station live 24/7 visit www.HealthcareNOWRadio.com or ask your Smart Device to “….Play Healthcare NOW Radio”. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen

The Land of the Rising Sun, once a powerhouse in research and development, saw its share of global innovation slip following the 1990s. Now, Japan's leaders are seeking to reigniting its innovation culture. Sam Lim, executive director of EastGate Capital Management, explains. (11/2025)

Research shows that women remain woefully underrepresented at the highest levels of leadership in the life sciences industry. Those who have broken through that glass ceiling, however, are not only doing groundbreaking work in pharma, biotech, medtech and beyond but also reframing what it means to be a leader in the sector—as evidenced by the often-unconventional career paths and management philosophies of the 10 women featured in this year’s Fiercest Women in Life Sciences report. In this week’s episode of “The Top Line,” Fierce’s Andrea Park and Gabrielle Masson dive into the report, highlighting several honorees’ paradigm-busting approaches to leadership, mentorship and building inclusive teams. To learn more about the topics in this episode: 2025's Fiercest Women in Life Sciences 4 reasons life sciences still fail women at the top, despite a female-majority workforce: report GSK's Emma Walmsley to step down as CEO in shock move, giving way to commercial lead Luke Miels Merck KGaA, grappling with geopolitical tensions, ⁠reveals CEO transition Takeda taps Julie Kim to take over for retiring CEO Christophe Weber See omnystudio.com/listener for privacy information.

Dr. Rachel Gatlin entered neuroscience with curiosity and optimism. Then came chaos. She started her PhD at the University of Utah in March 2020—right as the world shut down. Her lab barely existed. Her advisor was on leave. Her project focused on isolation stress in mice, and then every human on earth became her control group. Rachel fought through supply shortages, grant freezes, and the brutal postdoc job market that treats scientists like disposable parts. When her first offer vanished under a hiring freeze, she doubled down, rewrote her plan, and won her own NIH training grant. Her story is about survival in the most literal sense—how to keep your brain intact when the system built to train you keeps collapsing.RELATED LINKS• Dr. Rachel Gatlin on LinkedIn• Dr. Gatlin's Paper Preprint• Dr. Eric Nestler on Wikipedia• News Coverage: Class of 2025 – PhD Students Redefine PrioritiesFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this episode of Tiny Show and Tell Us, we talk about different ways of turning pennies all of the colors of the rainbow. Then we discuss an ongoing NASA mission to touch the sun.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Im Finale der dritten Staffel empfange ich meine ehemalige Vorgesetzte Susanne Schmutzler, Partnerin bei PwC und Leiterin des Bereichs Change Management. Nach 13 Jahren internationaler Tätigkeit bei Accenture bringt sie wertvolle Perspektiven zur deutschen Change-Landschaft mit.Deutschland liegt in Sachen Digitalisierung und Transformationsbereitschaft deutlich hinter internationalen Standards zurück. Schmutzler beschreibt, dass deutsche Organisationen wesentlich mehr Konkretion und ein klares "Warum" benötigen, während international ein visionärerer Ansatz üblich ist. Wir diskutieren Change Management in der Pharma-Branche, generationsübergreifende Herausforderungen und meine größte Frustration: den Mangel an Menschen, die Ideen aktiv mitgestalten statt nur konsumieren wollen.00:08 - Vorstellung und Hintergrund von Susanne Schmutzler03:30 - Deutschlands Digitalisierungsrealität und kulturelle Besonderheiten05:14 - Anpassung des Führungsstils: Mehr Konkretion statt Vision10:30 - Change Management in Life Sciences und Pharma18:45 - Generationendialog und demografischer Wandel28:00 - Work-Life-Integration und der Mensch im Mittelpunkt30:00 - Ziele für Pitstop Consulting und Ausblick auf Staffel 432:00 - Frustration und Motivation: Die Suche nach Mitgestaltern

EPISODE DESCRIPTIONBefore she was raising millions to preserve fertility for cancer patients, Tracy Weiss was filming reenactments in her apartment for the Maury Povich Show using her grandmother's china. Her origin story includes Jerry Springer, cervical cancer, and a full-body allergic reaction to bullshit. Now, she's Executive Director of The Chick Mission, where she weaponizes sarcasm, spreadsheets, and the rage of every woman who's ever been told “you're fine” while actively bleeding out in a one-stall office bathroom.We get into all of it. The diagnosis. The misdiagnosis. The second opinion that saved her life. Why fertility preservation is still a luxury item. Why half of oncologists still don't mention it. And what it takes to turn permission to be pissed into a platform that actually pays for women's futures.This episode is blunt, hilarious, and very Jewish. There's chopped liver, Carrie Bradshaw slander, and more than one “fuck you” to the status quo. You've been warned.RELATED LINKSThe Chick MissionTracy Weiss on LinkedInFertility Preservation Interview (Dr. Aimee Podcast)Tracy's Story in Authority MagazineNBC DFW FeatureStork'd Podcast EpisodeNuDetroit ProfileChick Mission 2024 Gala RecapFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

What if one decision could make or break your drug's success? Join Charles River's Sarah Gould as she unpacks the high-stakes, emotion-filled world of species selection—and why it's about so much more than science. Discover how this critical choice shapes safety, speeds development, and drives innovation in today's evolving research landscape.Show Notes Alternative Methods Advancement Project  | Charles River Animals in Research  | Charles River Research Models and Services | Charles River Research Animals Models | Charles River 

Bayer is reshaping its pharmaceutical business with a new operating model designed to enhance collaboration and bring research & development and commercialization closer together. In a recent episode of The Top Line podcast, Bayer executives Christine Roth, Executive Vice President and Head of Global Product Strategy and Commercialization, and Dr. Yesmean Wahdan, Head of Medical Affairs for the United States and North America, discussed how the company’s Dynamic Shared Ownership framework is driving faster innovation and helping accelerate the development of new therapies for patients. The model removes traditional hierarchies, empowers cross-functional teams and encourages real-time collaboration across departments. Roth and Wahdan said the approach has already shortened regulatory timelines, reduced resource use and helped deliver treatments to patients sooner. By embedding commercial insights early in the research process, Bayer teams can anticipate market needs and focus on the greatest areas of unmet medical demand. The leaders said the company’s collaborative culture keeps patient benefit at the center of decision-making. To learn more about how Bayer’s model is transforming its pipeline, listen to the full episode of The Top Line. See more from Bayer’s Christine Roth and Dr. Yesmean Wahdan on their LinkedIn profiles below: Christine: https://www.linkedin.com/in/christine-roth-34b07b18/ Yesmean: https://www.linkedin.com/in/yesmean-h-wahdan-md-71409b199/ See omnystudio.com/listener for privacy information.

In this special In Vivo podcast episode, executive editor Lucie Ellis-Taitt is joined by an expert panel of Citeline journalists – Ashley Yeo, David Wild, Jessica Merrill and data journalist Edwin Elmhirst – to explore the trends set to reshape the biopharma and medtech sectors as we head into 2026.

Venture capital funding into Irish technology SMEs rose by 8% to €207.9m in the third quarter of 2025, compared to the same period last year, according to the Irish Venture Capital Association Venture Pulse survey, published today in association with William Fry. Funding for the nine months to end September fell by 10% to €853.4m from €945.3m the previous year. The total number of deals in the same period fell from 153 to 135. "Third quarter data provided some relief following a dismal second quarter this year when funding fell to €112.6m, its lowest in ten years," commented Caroline Gaynor, chairperson, Irish Venture Capital Association. "Hopefully, we are starting to see some confidence and stability return to the market, but it remains a challenging time for early-stage companies." She added that following the blow to investor confidence caused by the United States' April 2nd tariff shocks, international investors had started to return to the market. International VC investment into Irish SMEs rose to €146.7 m in the current quarter compared to €69.5m in the second quarter of this year. She said that bright spots in the overall data were deals in the €1m- €5m range, which accounted for 30 out of the 39 transactions in this quarter. Transactions in the €1-€3m category rose by 35% to €35.6m compared to the same time last year. Deals in the €3-€5m range increased by 18% to €34.7m. However, funding in the €10m-€30m category fell by two-thirds to €26m while €5-€10m deals dropped by 74% to €13.5m, compared to the same quarter last year. There was better news in the €30m+ category where medtech company, ProVerum raised €62m, and AI machine learning firm, Nory raised €34m. Sarah-Jane Larkin, director general, IVCA, said that while there was some healthy activity, gaps remained in the third quarter, particularly in seed funding and transactions under €1m, both of which disappointed. Seed or first rounds fell by 30% to €23.4m from €33.5m, compared to the same quarter last year. Seed funding for the first nine months was down 31% to €88.3m from €127.2m last year. Despite this shortfall, the IVCA director general said: "The process for deploying the Government's €250m Enterprise Ireland Seed and Venture Capital Scheme 2025-29 is well underway. We are optimistic that the environment for very early stage Irish companies seeking first round funding will pick up in the first half of next year." Lifesciences was the most successful sector to date this year, raising funds of €361.6m or 42% of the total in the first nine months. This was followed by Cybersecurity at €136.3m (16%); AI and machine learning €97m (11%); Fintech €92.2m (11%) and Software €66.2m (8%). More about Irish Tech News Irish Tech News are Ireland's No. 1 Online Tech Publication and often Ireland's No.1 Tech Podcast too. You can find hundreds of fantastic previous episodes and subscribe using whatever platform you like via our Anchor.fm page here: https://anchor.fm/irish-tech-news If you'd like to be featured in an upcoming Podcast email us at Simon@IrishTechNews.ie now to discuss. Irish Tech News have a range of services available to help promote your business. Why not drop us a line at Info@IrishTechNews.ie now to find out more about how we can help you reach our audience. You can also find and follow us on Twitter, LinkedIn, Facebook, Instagram, TikTok and Snapchat.

Nick Galakatos, Senior Managing Director, & Global Head of Life Sciences at Blackstone joins Daniel Cassidy at the UBS podcast studio in New York for a comprehensive discussion on trends and developments within Life Sciences, including a look at funding innovations, the regulatory landscape, and the investment case for Life Sciences.

Send us a textIn this episode, an experienced angel investor explains how she evaluates founders, the value of firsthand problem knowledge, and why the best investments balance limited downside with exponential upside.Learn her million-dollar lesson: success comes from focusing on asymmetry, people, and time.https://familyoffices.com/

In this episode of EisnerAmper's Engaging Alternatives Spotlight, Elana Margulies-Snyderman, Director, Publications, speaks with Tadd Wessel, Managing Partner, Petrichor Capital, a New York-based investment firm which invests in health care managers and businesses to drive scientific and medical innovation. Tadd, formerly with OrbiMed Advisors and Fortress Investment Group, shares his outlook for growth capital investing in health care, including the greatest opportunities, challenges and more. ✨ What you'll learn:

Most of us know the story of the Titanic. In 1912, the massive — supposedly indestructible — steamship sank after hitting an iceberg on its first and only journey across the Atlantic Ocean. Titanic remained undiscovered on the seafloor, somewhere in the North Atlantic Ocean, for 73 years, until it was found nearly two miles beneath the surface. But now the ship might be disappearing again, this time for good. And the culprit is not another iceberg — it's something much, much smaller. Send us your science facts, news, or other stories for a chance to be featured on an upcoming Tiny Show and Tell Us bonus episode. And, while you're at it, subscribe to our newsletter!Links to the Tiny Show and Tell stories are here and here. All Tiny Matters transcripts and references are available here.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Have you ever wondered why your dog takes such a long time to sniff a patch of grass? Or why flies buzz around so sporadically? It’s because most of what a creature actually senses is invisible to us. They perceive their world as differently as we perceive our own. Pulitzer Prize winning science writer Ed Yong wrote a book about this called An Immense World: How Animal Senses Reveal the Hidden Realms Around Us. Join me for a fun conversation with Ed about the astonishing ways animals sense the world around us. From birds that navigate the open ocean by smell, to penguins that sense vibrations underground. By learning how animals perceive their world, it just might change the way we perceive them, and make us look at our own world a little differently. Check out our episode about AI and Animal Communication: Digital Dr. Dolittle: decoding animal conversations with artificial intelligence. Enjoy BONUS CONTENT and help us continue to create this special immersive storytelling by joining THE WILD Patreon community at www.patreon.com/chrismorganwildlife and you can donate to KUOW at kuow.org/donate/thewild. Thank you. Follow us on Instagram @chrismorganwildlife and @thewildpod for more adventures and behind the scenes action! THE WILD is a production of KUOW in Seattle in partnership with Chris Morgan Wildlife and Wildlife Media. It is produced by Matt Martin and Lucy Soucek, and edited by Jim Gates. It is hosted, produced and written by Chris Morgan. Fact checking by Apryle Craig. Our theme music is by Michael Parker.See omnystudio.com/listener for privacy information.

EPISODE DESCRIPTION:Libby Amber Shayo didn't just survive the pandemic—she branded it. Armed with a bun, a New York accent, and enough generational trauma to sell out a two-drink-minimum crowd, she turned her Jewish mom impressions into the viral sensation known as Sheryl Cohen. What started as one-off TikToks became a career in full technicolor: stand-up, sketch, podcasting, and Jewish community building.We covered everything. Jew camp lore. COVID courtship. Hannah Montana. Holocaust comedy. Dating app postmortems. And the raw, relentless grief that comes with being Jewish online in 2025. Libby's alter ego lets her say the quiet parts out loud, but the real Libby? She's got receipts, range, and a righteous sense of purpose.If you're burnt out on algorithm-friendly “influencers,” meet a creator who actually stands for something. She doesn't flinch. She doesn't filter. And she damn well earned her platform.This is the most Jewish episode I've ever recorded. And yes, there will be guilt.RELATED LINKSLibby's Website: https://libbyambershayo.comInstagram: https://www.instagram.com/libbyambershayoTikTok: https://www.tiktok.com/@libbyambershayoLinkedIn: https://www.linkedin.com/in/libby-walkerSchmuckboys Podcast: https://jewishjournal.com/podcasts/schmuckboysForbes Feature: Modern Mrs. Maisel Vibes https://www.forbes.com/sites/joshweissMedium Profile: https://medium.com/@libbyambershayoFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform.For guest suggestions or sponsorship, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Welcome back to another episode of the EUVC Podcast, your trusted inside track on the people, deals, and dynamics shaping European venture.This week, Andreas Munk Holm is joined by Mariette Roesink, Co‑Founder of Curie Capital. Named after Marie Curie, the fund backs breakthrough life science technologies with a mission to both deliver outsized returns and transform patient outcomes.Mariette and her co-founder Han de Groot have already been part of two unicorn exits, raised €200M across their portfolio in a single year, and — most strikingly — can point to zero bankruptcies across 25 investments. As family office-backed GPs, they also invest significant personal capital alongside LPs.They dive into Curie's approach, the unique dynamics of European biotech, why Western Europe is a life science powerhouse, and how to make life science VC anything but “binary.”Whether you're an LP curious about the sector, a GP sharpening your pitch, or a founder in healthtech — this conversation is packed with insights.Here's what's covered:01:00 | Why Curie Capital is named after Marie Curie03:00 | High financial returns + patient impact: the dual promise of biotech05:00 | Why GPs investing their own family money matters07:00 | Raising €200M in “harsh” markets — portfolio highlights09:30 | The billion-dollar impact story of Acerta Pharma12:00 | Building specialist networks & engaging strategics early14:00 | TargED Biotherapeutics: developing a breakthrough stroke therapy17:00 | Zero bankruptcies — besides capital Curie helps theyoung ventures with their network to support raising next roundsand partnering20:00 | The Curie Capital team — science, business, and hands-on support21:30 | Why Western Europe is a life sciences powerhouse23:30 | The 6.1x valuation gap between EU & US early-stage biotech25:00 | The truth about life science holding periods & exits27:00 | Educating LPs: why life science VC isn't as binary as many think

Send us a textMany people do not understand the workings of a land grant university, especially its ongoing connection to agriculture. In 2025, Dean Leslie Edgar got the opportunity to return to her home state of Idaho to become the Dean of the College of Agricultural and Life Sciences at the University of Idaho.In this podcast, Dean Edgar answers question of how the university works with farmers, communities, industry leaders, and most important - students. She tell how her upbringing helped her have a passion for the advancement of agriculture and shares how recent developments and facilities are going to help innovate solutions for the future of farming and ranching.

(0:00) Intro(1:55) About the podcast sponsor: The American College of Governance Counsel(2:42) Start of interview(3:56) Sue's origin story(5:42) The Rise of Biotech and her Career Journey (BioRad, Dupont, Amersham and Affymetrix)(12:04) Transition to Venture Capital (Mohr Davidow Ventures, GE Ventures)(14:55) Evolution of Corporate Venture Capital (since ~2010) "They [now] represent about 28% of all VC dollars going into startups."(19:32) Her Board Membership Journey (since 2000, as a board member at Affymetrix where she was an executive)(21:12) The Impact of AI on Governance(21:53) Cultural Differences in Boardrooms between founders and investors: "if you do governance right, it should be an enabler, not a suffocator."(29:24) Navigating Geopolitical Risks. Example: Align Technology: We moved about 90% of our Russia based developers to Armenia.(33:01) Challenges in Life Sciences Funding(34:52) The AI Investment Boom(37:16) Activism's Influence on Corporate Boards. "They punish the lack of communication. They punish obscuring things."  Reference to E189 with Joele Frank and Anne Chapman.(42:36) The Evolution of Compensation Structures "I think one of the key topics around comp is aligning pay, performance, and purpose."(45:34) Other relevant board topics: human capital, innovation, data and board culture.(47:57) The Importance of Board Refreshment (digital and IA natives that can govern in the boardroom)(49:12) Books that have greatly influenced her life:Passages by Gael Sheehy (1976)Mountains Beyond Mountains by Tracy Kidder (2003)(52:00) "People that helped her along"(54:23) An unusual habit or an absurd thing that she loves. (54:59) The living person she most admires: Francis Collins.(56:39) Quotes that she thinks of often or lives her life by.Sue Siegel is a highly accomplished executive, investor, and board member who has been at the forefront of innovation across life sciences, healthcare, and technology for more than three decades. You can follow Evan on social media at:X: @evanepsteinLinkedIn: https://www.linkedin.com/in/epsteinevan/ Substack: https://evanepstein.substack.com/__To support this podcast you can join as a subscriber of the Boardroom Governance Newsletter at https://evanepstein.substack.com/__Music/Soundtrack (found via Free Music Archive): Seeing The Future by Dexter Britain is licensed under a Attribution-Noncommercial-Share Alike 3.0 United States License

When the system kills a $2.4 million study on Black maternal health with one Friday afternoon email, the message is loud and clear: stop asking questions that make power uncomfortable. Dr. Jaime Slaughter-Acey, an epidemiologist at UNC, built a groundbreaking project called LIFE-2 to uncover how racism and stress shape the biology of pregnancy. It was science rooted in community, humanity, and truth. Then NIH pulled the plug, calling her work “DEI.” Jaime didn't quit. She fought back, turning her grief into art and her outrage into action. This episode is about the cost of integrity, the politics of science, and what happens when researchers refuse to stay silent.RELATED LINKS• The Guardian article• NIH Grant• Jaime's LinkedIn Post• Jaime's Website• Faculty PageFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Europe leads the world in discovery — yet too often, its breakthroughs never become global companies.Billions in research funding turn into patents, not products.While others build empires from ideas, Europe risks becoming the world's laboratory — brilliant, but broke.That's the paradox at the heart of this conversation.In this episode, Karl Nehammer, Vice-President of the European Investment Bank (EIB) and former Chancellor of Austria, joins Christian Soschner live at BIO-Europe 2025 to discuss how Europe can turn its world-class science into world-class companies.He shares how leadership forged in crisis can rebuild confidence, competitiveness, and growth — and why every crisis hides an opportunity to start thinking differently.

As we approach episode 100 of Tiny Matters, we wanted to talk about how it all got started nearly 4 years ago and where we are headed! How did Sam and Deboki become co-hosts? What have they learned about the types of stories and episodes they are drawn to? What happens if an interview goes poorly? What is the American Chemical Society (ACS)? How about Multitude? Will we get 100 MORE episodes of the show? And more... See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

EPISODE DESCRIPTIONAllison Applebaum was supposed to become a concert pianist. She chose ballet instead. Then 9/11 hit, and she ran straight into a psych ward—on purpose. What followed was one of the most quietly revolutionary acts in modern medicine: founding the country's first mental health clinic for caregivers. Because the system had decided that if you love someone dying, you don't get care. You get to wait in the hallway.She's a clinical psychologist. A former dancer. A daughter who sat next to her dad—legendary arranger of Stand By Me—through every ER visit, hallway wait, and impossible choice. Now she's training hospitals across the country to finally treat caregivers like patients. With names. With needs. With billing codes.We talked about music, grief, psycho-oncology, the real cost of invisible labor, and why no one gives a shit about the person driving you to chemo. This one's for the ones in the waiting room.RELATED LINKSAllisonApplebaum.comStand By Me – The BookLinkedInInstagramThe Elbaum Family Center for Caregiving at Mount SinaiFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Episode 472 features Dr. Sheila Gujrathi, a biotech entrepreneur, executive, and champion for under represented leaders. Her new book, "The Mirror Effect: A Transformative Approach To Growth For The Next Generation Of Female Leaders" is out now.Chapters:00:00 Introduction and Book Announcement02:15 The Unmet Need: Writing for My Younger Self05:30 Overcoming Challenges: A Personal Journey09:45 The Power of Mentorship and Sponsorship14:00 Spiritual Growth and Finding Purpose18:20 Building a Personal Board of Directors23:10 The Inner Critic and Self-Compassion28:45 The Importance of Storytelling in Leadership33:00 Navigating Negative Work Environments37:15 Conclusion: Embracing Vulnerability and ConnectionFind Sheila Online:Website: ​​https://sheilagujrathimd.com/ TEDxTalk: https://www.youtube.com/watch?v=2DpDx6T3-X4 LinkedIn: https://www.linkedin.com/in/sheila-gujrathi-md/ Instagram: https://www.instagram.com/sheilagujrathimd/ Book: https://sheilagujrathimd.com/book/ About Sheila:Sheila is a biotech entrepreneur, executive, and champion for under represented leaders. Over the past 25 years, she's had the privilege of developing life-changing medicines for patients with serious diseases while building and running private and public biotech companies—including some exciting exits. Today she's a founder, chairwoman, board director, strategic advisor, and consultant to start-up companies and investment funds. Dr. Gujrathi was the co-founder and former CEO of Gossamer Bio and former Chief Medical Officer of Receptos. Her journey started at Northwestern University, where she earned both her M.D. and biomedical engineering degree, and took her from the halls of Harvard, UCSF, and Stanford to the corporate offices of Fortune 500 companies like McKinsey, Genentech, and Bristol-Myers Squibb.Dr. Gujrathi has earned multiple leadership awards, including AIMBE Fellow, BLOC100 Luminary, Healthcare Technology Report Top 25 Women Leaders in Biotechnology, Corporate Directors Forum Director of the Year, and Fiercest Women in Life Sciences. But what really lights her up is creating the inclusive environments she wished she'd had throughout her career. That's why she co-founded the Biotech CEO Sisterhood, a group of trailblazing female CEOs—because we're all better when we support each other.

In this episode, join Michael Sullivan, Senior Vice President, Product Supply Chain NA, Bayer and James Hoskins, Vice President, Operations, Life Sciences and Healthcare, DHL Supply Chain, as they explore our 25-year partnership, organizational strategy and successful collaborations. 

In part two of our conversation with Brian Scanlan, Advisor of Life Sciences at Edgewater Capital Partners, we explore how today's CDMO funding trends are shaping the next phase of growth and specialization across the contract research and manufacturing ecosystem. Brian shares his perspective on: The outlook for cell and gene therapies, where clinical setbacks, overcapacity, and high costs are balanced by steady innovation and cautious optimism; Why “specialization over scale” is defining the next wave of CDMO success, as niche providers in radiopharma, peptides, and other complex modalities gain traction; and How the evolving Biosecure Act and U.S. reshoring efforts are reshaping global supply chains and creating new opportunities for domestic manufacturing.

The healthcare marketing landscape is evolving fast — shaped by regulatory shifts, patient empowerment, and the rise of digital health marketplaces. In this episode of The Top Line, sponsored by Havas Media Network, host Chris Hayden sits down with Holly Dunn, Managing Partner of Performance at Havas Media Network, to explore how pharma brands can redefine patient engagement for a more connected, equitable future. Dunn explains how first-party data, AI-driven intent signals, and curated health marketplaces are enabling more compliant, transparent, and human-centered campaigns. She also discusses the growing role of healthcare creators, the fight against misinformation, and strategies to ensure high-quality, privacy-safe engagement across the patient journey. If you’re in pharma or biotech marketing, this conversation offers critical insight into how leading brands are building trust and equity in an increasingly complex environment.See omnystudio.com/listener for privacy information.

My guest today is Jeff Skopek, a Professor of Law and the Deputy Director of the Centre for Law, Medicine, and Life Sciences at the University of Cambridge. He holds a J.D. from Harvard Law School and a Ph.D. in the History and Philosophy of Science from the University of Cambridge.His research explores the normative and conceptual foundations of health law, focusing in particular on the health care system, biomedical research, and controversies about what constitutes a harm or benefit within medical care. His recent research also focuses on animal rights. He joins us today to discuss a work in progress, Created To Be Killed.Show NotesAbout Jeff SkopekAbout Kim KrawiecAbout Mason Marché

On the Thursday, Oct. 30 edition of Georgia Today: The parent company of Georgia Power beats Wall Street expectations; Gwinnett County will soon get a new life sciences research park; and frustration builds as the government shutdown continues.

If you're a female and you want to use a contraceptive pill, patch, injection, or device, you have over 250 options. But if you're a male and you want a contraceptive, you have three options. You can get a vasectomy, you can use condoms, which can have up to a 18% failure rate, or you can use what sex researchers politely call “the withdrawal method,” which is highly unreliable. But there could be another male contraceptive very soon. So what took so long?Send us your science facts, news, or other stories for a chance to be featured on an upcoming Tiny Show and Tell Us bonus episode. And, while you're at it, subscribe to our newsletter!Links to the Tiny Show and Tell stories are here and here. All Tiny Matters transcripts and references are available here.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

EPISODE DESCRIPTIONRebecca V. Nellis never meant to run a nonprofit. She just never left. Twenty years later, she's still helming Cancer and Careers after a Craigslist maternity-leave temp job turned into a lifelong mission.In this 60-minute doubleheader, we cover everything from theater nerdom and improv rules for surviving bureaucracy, to hanging up on Jon Bon Jovi, to navigating cancer while working—or working while surviving cancer. Same thing.Rebecca's path is part Second City, part Prague hostel, part Upper East Side grant writer, and somehow all of that makes perfect sense. She breaks down how theater kids become nonprofit lifers, how “sample sale feminism” helped shape a cancer rights org, and how you know when the work is finally worth staying for.Also: Cleavon Little. Tap Dance Kid. 42 countries. And one extremely awkward moment involving a room full of women's handbags and one very confused Matthew.If you've ever had to hide your diagnosis to keep a job—or wanted to burn the whole HR system down—this one's for you.RELATED LINKSCancer and CareersRebecca Nellis on LinkedIn2024 Cancer and Careers Research ReportWorking with Cancer Pledge (Publicis)CEW FoundationI'm Not Rappaport – Broadway InfoFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship opportunities, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

On this special segment of The Full Ratchet, the following Investors are featured: Barry Schuler of DFJ Growth Ventures Shashank Saxena of Sierra Ventures Jeff Bussgang of Flybridge Capital We asked guests to discuss the most visionary founder that they've worked with and what makes them so special. The host of The Full Ratchet is Nick Moran of New Stack Ventures, a venture capital firm committed to investing in founders outside of the Bay Area. We're proud to partner with Ramp, the modern finance automation platform. Book a demo and get $150—no strings attached.   Want to keep up to date with The Full Ratchet? Follow us on social. You can learn more about New Stack Ventures by visiting our LinkedIn and Twitter.

Erin Silva, Ph.D. https://cias.wisc.edu/directory/17158/FoA 280: Organic Farming Myths and Realities With Erin SilvaI wanted to invite Erin Silva back on the show to hear about her continued work with farmers that are going down the path of organic AND regenerative. On the surface, those two farming approaches are easy to get behind: let's try to reduce our dependence on synthetic chemistry and let's try to build soil health over time while still farming intensively and profitably. But in practice, there are tradeoffs. To promote more living roots on the soil through cover crops, as one example, farmers need a way to terminate those cover crops and using herbicides for that is really really helpful. So I'm intrigued about how farmers are making these systems work and how scientists like Erin our doing the critical research to understand how these practices can work on more acres for more farmers. So that is what today's episode is all about, and for context I'll give you a brief bio on our guest. Dr. Erin Silva is an Associate Professor and State Extension Specialist in Organic and Sustainable Cropping Systems in the Department of Plant Pathology as well as the Director for the Center for Integrated Agricultural Systems in the College of Agricultural and Life Sciences at UW-Madison. Her research influences the strong organic sector that contributes to Wisconsin's agricultural economy, with Wisconsin second only to California as the state with the greatest number of organic farms. In continued support of these farms and the organic sector within the state, nation, and globally, her research and scholarly contributions continue to be directed in the broad area of the biology and agroecology of organic crop management, with emphases on cover crops, soil health, and genotype/ environment interactions. Dr Silva earned her Ph.D. in Horticulture at Washington State University.